In the study, outcomes among 606 Nx2me users and contemporary matched controls were compared.1 Nx2me users comprised both patients already established on home hemodialysis with the NxStage System One and new home hemodialysis patients. In patients who began to use Nx2me within 3 months after initiating home hemodialysis, technique failure was reduced by 34%, relative to matched controls.1 Additionally, patients who began to use Nx2me during home hemodialysis training were 61% more likely to complete training and did so in 7 fewer days, relative to matched controls.1
A key component of the Nx2me platform is the Nx2me iPad® app, which is designed to increase patients' ease of use of home therapy by capturing treatment data and wirelessly sending it to their center after each treatment, thereby reducing the need for paper flow sheets. Dialysis center staff can access the treatment data, sent through a secured and encrypted web server, using the Nx2me Clinician Portal. The timely receipt of electronic flowsheets from the Nx2me app allows for early intervention to help reduce patient complications and hospitalizations. In addition, Nx2me integrates with center EMR systems to provide clinicians with treatment and billing information.
"Nx2me provides the tools to support and proactively engage with patients," said,
For more information about Nx2me and home hemodialysis with the NxStage System One, please visit www.NxStage.com.
The NxStage System One is a prescription device and, like all medical devices, involves some risks. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream, and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed. Patients should consult with their doctor to understand the risks and responsibilities of home and/or more frequent hemodialysis using the NxStage System One. Additionally, the reported benefits of home and/or more frequent hemodialysis may not be experienced by all patients.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the
About NxStage Medical
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the
References: 1. Weinhandl ED, Collins AJ. Relative risk of home hemodialysis attrition in patients using a telehealth platform. Hemodial Int. 2017. http://onlinelibrary.wiley.com/doi/10.1111/hdi.12621/full
View original content with multimedia:http://www.prnewswire.com/news-releases/nx2me-connected-health-improves-home-hemodialysis-retention-300568624.html
Media contact: Kristen K. Sheppard, Esq., Vice President, Associate General Counsel, +1-978-332-5923